NCT00089167View on ClinicalTrials.gov

Melphalan, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed, Previously Untreated Primary Systemic Amyloidosis

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

May 31, 2002

Primary Completion Date

December 31, 2007

Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
BIOLOGICAL

filgrastim

DRUG

dexamethasone

DRUG

melphalan

DRUG

thalidomide

Trial Locations (1)

10021

Memorial Sloan-Kettering Cancer Center, New York

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT00089167 - Melphalan, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed, Previously Untreated Primary Systemic Amyloidosis | Biotech Hunter | Biotech Hunter